Table 3.
Outcomes of propensity-matched HCV uninfected recipients from HCV uninfected donors (HCV D Ab−, NAT−/R Ab−), vs. HCV seropositive, non-viremic donors (HCV D Ab+, NAT− / R Ab−) and HCV viremic (HCV Ab± ,NAT+/R Ab−) donors.*
| D Ab−,NAT−/ R Ab− (n = 659) | D Ab+, NAT− / R Ab− (n = 349) | p value | D Ab−, NAT− / R Ab− (n = 350) | D Ab±, NAT+/ R Ab− (n =191) | p value | |
|---|---|---|---|---|---|---|
| Post-transplant follow-up time, mean (SD),years | 1.2 (0.9) | 0.5 (0.5) | <0.001 | 1.2 (0.9) | 0.6 (0.8) | <0.001 |
| Primary Outcomes | ||||||
| LOS mean (SD), days | 6.3 (8.1) | 6.1 (8.3) | 0.70 | 6.0 (4.8) | 5.6 (4.1) | 0.35 |
| DGF, n (%) | 230 (35.2) | 66 (18.9) | <0.001 | 123 (36.2) | 32 (16.8) | <0.001 |
| Acute rejection at 6 months, n (%) | 25 (4.2) | 4 (2.0) | 0.05 | 13 (5.3) | 4 (4.4) | 0.72 |
| Scr at 6 months, mean (SD), mg/dl | 1.49 (0.75) | 1.29 (0.27) | 0.19 | 1.56 (0.48) | 1.26 (0.33) | 0.01 |
| eGFR† at 6 months, mean, (SD) ml/min/1.73 m2 | 55.6 (22.6) | 60.9 (14.9) | 0.25 | 54.1 (19.3) | 68.3 (17.4) | 0.004 |
| Secondary Outcomes | ||||||
| Overal graft survival at 12 months, % | 92.8 | 94.3 | 0.72 | 94.2 | 98.4 | 0.17 |
| Patient survival at 12 months, % | 96.7 | 96.3 | 0.85 | 97.2 | 100 | 0.23 |
| Overall graft failure risk at 12 months post-transplant | Reference | HR (95% CI) | Reference | HR (95% CI) | P value | |
| Univariate | - | 0.81 (0.42–1.60) | 0.55 | - | 0.61 (0.21–1.83) | 0.39 |
| Multivariable‡§ | - | 0.60 (0.23–1.29) | 0.19 | - | 0.85 (0.25–2.96) | 0.17 |
Ab, Antibody; cPRA, Calculated panel reactive antibodies; D, Donor; DGF, Delayed graft function; eGFR, Estimated Glomerular filtration rate; HCV, Hepatitis C Virus; LOS, Length of stay; NAT, Nucleic acid testing; R, Recipient; Scr, Serum Creatinine.
The propensity matching was performed based on variables including recipient age (year), gender, race (AA, non-AA), cause of ESRD (DM, HTN, GN, PKD, others), diabetes status, re-transplant status, share type (local, regional, national), donor DCD status, induction type (no-induction, IL2-RA, r-ATG, alemtuzumab), cold ischemia time (hour), and donor KDPI score category (0–20, 21–50, 51–80, 81–100%), cPRA (0–20%, 21–80%, 81–100%), wait-list time (0–1, 1–3, >3 years), and dialysis vintage (preemptive, 0–1, 1–3, >3 years).
eGFR was calculated using the Modification of Diet in Renal Disease Study (MDRD) equation.
Cox proportional hazard analysis
Multivariable proportional Cox hazard analysis adjusted for BMI (BMI<35, BMI ≥35), transplant year, HLA mismatch, time and the UNOS Region.